DRW Securities LLC Makes New $385,000 Investment in Danaher Co. (NYSE:DHR)

DRW Securities LLC purchased a new stake in shares of Danaher Co. (NYSE:DHR) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,540 shares of the conglomerate’s stock, valued at approximately $385,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Oak Thistle LLC bought a new stake in Danaher in the second quarter worth about $363,000. Caden Capital Partners LP raised its holdings in shares of Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares in the last quarter. JARISLOWSKY FRASER Ltd lifted its stake in Danaher by 10.8% during the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after purchasing an additional 55,908 shares during the last quarter. HighPoint Advisor Group LLC bought a new stake in Danaher during the fourth quarter worth approximately $2,614,000. Finally, Norden Group LLC acquired a new position in Danaher in the first quarter worth approximately $4,151,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Jefferies Financial Group started coverage on shares of Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Trading Up 0.2 %

NYSE:DHR opened at $273.19 on Tuesday. The company has a market capitalization of $202.35 billion, a P/E ratio of 46.30, a P/E/G ratio of 4.48 and a beta of 0.83. The stock’s 50 day moving average price is $268.16 and its 200 day moving average price is $257.32. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.05 EPS. On average, research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Insider Activity

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.